Pancreatic cancer is often deadly not because it’s the most aggressive, but because it’s usually diagnosed too late. By the time symptoms appear, the disease has often spread, leaving patients with limited treatment options. Despite its relatively low incidence, pancreatic cancer is the fourth leading cause of cancer death in the U.S., with a five-year survival rate that still hovers below 13%.
A new blood test developed by researchers at Oregon Health & Science University could change that. Called PAC-MANN, this test detects pancreatic cancer earlier — before symptoms show — using just a small blood sample. It’s fast, inexpensive, and more accurate than current tools. While it’s still being validated in trials, PAC-MANN could represent a major step toward catching pancreatic cancer when it’s still treatable.
Why Early Detection in Pancreatic Cancer Has Been So Elusive
Pancreatic cancer is among the most lethal forms of cancer, largely because it’s usually detected too late for effective treatment. The most common type, pancreatic ductal adenocarcinoma (PDAC), makes up over 80% of cases and has a particularly grim prognosis. Despite being less common than cancers like breast, lung, or colorectal, pancreatic cancer ranks as the fourth leading cause of cancer-related deaths worldwide. In the United States alone, it claims close to 40,000 lives annually. The five-year survival rate remains under 13%, a figure that has only marginally improved over decades. The reason isn’t that the disease is inherently more aggressive than others — it’s that by the time it’s found, the window for successful treatment has usually already closed.
The main challenge lies in how silently pancreatic cancer develops. Unlike breast or colon cancers, which can often be caught early through routine screenings, pancreatic tumors grow quietly in a deep part of the abdomen, where they’re hard to detect with standard imaging. Symptoms such as abdominal pain, weight loss, or jaundice typically don’t appear until the disease is already advanced. By then, the cancer has often spread beyond the pancreas, limiting the effectiveness of surgery and other treatments. Most current diagnostic tools aren’t sensitive enough to catch the disease in its early stages, especially in people who aren’t showing any signs of illness.
Because of this, researchers and clinicians have been urgently working to develop noninvasive tools that can detect pancreatic cancer earlier and more reliably. The goal is to find a test that doesn’t require expensive or invasive procedures and that can be used to identify cancer before symptoms emerge — when more treatment options are still on the table. For a cancer this aggressive, early detection isn’t just helpful — it’s essential.
What the PAC-MANN Test Does Differently
The PAC-MANN blood test is a new diagnostic tool developed to catch pancreatic cancer before symptoms begin — a major step forward given how late the disease is usually diagnosed. Developed by researchers at Oregon Health & Science University (OHSU), the test works by detecting the activity of specific enzymes called proteases in the blood. These enzymes are typically elevated in people with pancreatic cancer, and by measuring their activity, the test can identify cancer-related changes that are invisible to conventional blood tests or imaging.
What sets PAC-MANN apart is its ability to distinguish between blood samples from individuals with pancreatic cancer, healthy individuals, and even those with non-cancerous pancreatic diseases — with 98% accuracy. That’s a major leap over the commonly used CA 19-9 test, which has limitations in both sensitivity and specificity. The CA 19-9 test often misses early-stage tumors and can return false positives in people with other conditions, like pancreatitis. By combining PAC-MANN with CA 19-9, researchers found they could detect early pancreatic cancer 85% of the time — a substantial improvement over using CA 19-9 alone.
The PAC-MANN test also offers practical advantages. It only requires a small blood sample — essentially a pinprick — and delivers results in about 45 minutes. That makes it not only more accurate but also faster and easier to use than many current methods. It could be particularly useful for screening people at higher risk, such as those with a family history of pancreatic cancer or certain genetic predispositions.
Importantly, this test isn’t limited to detection. Researchers also observed that PAC-MANN may be able to track how well a patient is responding to treatment. When therapies are effective, the enzyme activity that PAC-MANN measures tends to drop. This kind of real-time monitoring could help clinicians adjust treatment strategies earlier and more precisely, improving outcomes without having to wait for follow-up scans or imaging results.
The Rise of Liquid Biopsies in Early Cancer Detection
PAC-MANN is part of a broader shift in oncology toward liquid biopsies — tests that analyze blood or other easily collected bodily fluids for signs of cancer. Unlike traditional biopsies, which require removing tissue through invasive procedures, liquid biopsies can be done with a simple blood draw. They’re faster, less risky, and potentially much more scalable, especially for early detection and ongoing monitoring.
Over the last decade, liquid biopsy research has accelerated, driven by the promise of detecting cancer earlier, when treatments are more likely to work. Many of these tests focus on fragments of DNA shed by tumors into the bloodstream, known as circulating tumor DNA (ctDNA). Others look for proteins, enzymes, or metabolic markers — all of which can change in response to cancer. PAC-MANN belongs to this second group. Instead of scanning for genetic material, it measures enzyme activity, giving it a different and potentially complementary role alongside existing DNA-based tests.
This focus on enzyme activity is what gives PAC-MANN its edge, particularly for pancreatic cancer, where ctDNA tests have struggled due to the low levels of circulating tumor DNA in early stages. Enzyme activity changes can often be detected even when tumors are small or before they start shedding significant DNA into the blood. That makes tests like PAC-MANN a strong candidate for earlier-stage detection, especially when combined with other tools.
The development of PAC-MANN also highlights a practical direction for cancer screening. It doesn’t require specialized imaging equipment or extensive lab infrastructure, making it easier to deploy in clinical settings — including smaller hospitals or community clinics. This kind of accessibility is critical if early cancer detection is going to scale beyond academic medical centers and reach people before symptoms drive them to seek care.
What You Can Do: Practical Steps If You’re at Risk
While there’s still no routine screening test for the general population, people with a higher risk of pancreatic cancer can take steps to be proactive about their health. If you have a family history of pancreatic cancer, certain inherited genetic mutations (like BRCA1, BRCA2, or Lynch syndrome), or chronic pancreatitis, your risk may be elevated — and it’s worth discussing screening options with your doctor.
One important step is to talk to your primary care provider or a genetic counselor about your personal and family history. In some cases, you may qualify for surveillance programs that use imaging or blood tests like CA 19-9. While these aren’t perfect, they may help catch early changes in people who are considered high-risk.
Lifestyle also matters. Chronic smoking, obesity, and type 2 diabetes have all been linked to higher rates of pancreatic cancer. While making changes won’t eliminate your risk entirely, quitting smoking, maintaining a healthy weight, and managing blood sugar levels can reduce your overall risk and improve your health in other areas. No test or diet guarantees protection, but avoiding known risk factors helps shift the odds.
Also, be mindful of persistent, unexplained symptoms — especially if you fall into a higher-risk group. Ongoing fatigue, changes in appetite, unexplained weight loss, or abdominal discomfort shouldn’t be ignored. While these symptoms are often caused by more common conditions, bringing them up early with your healthcare provider allows for appropriate follow-up and potentially earlier diagnosis.
Finally, keep an eye on new developments like the PAC-MANN test. While it’s not widely available yet, trials are underway. If you’re part of a high-risk group, especially at a research center or large academic hospital, you may have access to investigational screening tools or be eligible for studies aiming to catch pancreatic cancer earlier.
A Step Toward Earlier Answers — and Better Outcomes
The PAC-MANN test isn’t a cure for pancreatic cancer, but it represents a meaningful shift toward earlier, more accessible diagnosis — something this disease has lacked for decades. By detecting subtle changes in enzyme activity from a simple blood sample, PAC-MANN could help flag pancreatic cancer before it spreads, when treatment is more likely to work. That kind of early insight can make the difference between a cancer that’s manageable and one that’s already too far along to treat effectively.
What makes this development promising is its potential to change how — and when — doctors can intervene. If validated in larger trials, PAC-MANN could become part of routine care for people at higher risk, or even integrated with other tests to improve accuracy across the board. And because the test is quick, low-cost, and minimally invasive, it holds promise not just for detection but also for monitoring how well treatments are working, helping clinicians tailor decisions in real time.
While this test isn’t yet ready for broad rollout, it’s a reminder that innovation in cancer care doesn’t always mean new drugs or surgeries — sometimes, the real breakthrough is simply knowing what you’re facing early enough to do something about it.
